Collaborations
The CANDY consortium maintains close collaborations with several scientific related projects.
AIMS-2-TRIAL
BIND
PRIME
PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded through an EU Horizon 2020 grant (No 847879). From 2020 – 2024, PRIME aims to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, neurodevelopmental disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions. Through PRIME we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.
Please find more information in the PRIME project Summary and on the project website of PRIME
R2D2-MH
More information about R2D2-MH, please visit the project website.